Regeneron Pharmaceuticals (MEX:REGN) Cyclically Adjusted FCF per Share: MXN514.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:REGN Regeneron Pharmaceuticals Inc MEX:REGN
87 GF Score
Price MXN10,835.99
GF Value MXN15,044.82
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share?

Regeneron Pharmaceuticals MEX:REGN 87 Cyclically Adjusted FCF per Share is MXN514.48 as of Mar. 2026. GuruFocus rates MEX:REGN with a GF Score™ of 87/100 and a GF Value™ of MXN15,044.82 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN133.847. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN514.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 13.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 15.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 26.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 45.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Regeneron Pharmaceuticals was 88.60% per year. The lowest was -7.40% per year. And the median was 9.80% per year.

As of today (2026-07-24), Regeneron Pharmaceuticals's current stock price is MXN10835.99. Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN514.48. Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 21.06.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Regeneron Pharmaceuticals was 506.10. The lowest was 18.28. And the median was 54.80.


Regeneron Pharmaceuticals  (MEX:REGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=10835.99/514.48
=21.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Regeneron Pharmaceuticals was 506.10. The lowest was 18.28. And the median was 54.80.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 309.84 363.44 373.27 520.88 508.41

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 550.23 520.16 520.41 508.41 514.48

MEX:REGN vs ALNY, RVMD, ONC: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


MEX:REGN
87GF Score
Regeneron Pharmaceuticals Inc MEX:REGN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=133.847/330.2130*330.2130
=133.847

Current CPI (Mar. 2026) = 330.2130.

Regeneron Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 41.474 241.018 56.823
201609 88.400 241.428 120.909
201612 42.835 241.432 58.587
201703 49.964 243.801 67.673
201706 -13.295 244.955 -17.922
201709 55.079 246.819 73.689
201712 78.019 246.524 104.505
201803 85.288 249.554 112.854
201806 48.497 251.989 63.552
201809 56.343 252.439 73.702
201812 110.028 251.233 144.617
201903 138.171 254.202 179.487
201906 15.706 256.143 20.248
201909 75.303 256.759 96.846
201912 106.989 256.974 137.481
202003 107.543 258.115 137.582
202006 159.265 257.797 204.003
202009 -79.035 260.280 -100.270
202012 189.799 260.474 240.616
202103 102.334 264.877 127.576
202106 85.912 271.696 104.415
202109 592.200 274.310 712.887
202112 401.163 278.802 475.137
202203 345.036 287.504 396.291
202206 72.495 296.311 80.789
202209 -78.534 296.808 -87.373
202212 250.782 296.797 279.017
202303 172.107 301.836 188.288
202306 133.734 305.109 144.737
202309 140.457 307.789 150.690
202312 115.879 306.746 124.744
202403 194.757 312.332 205.907
202406 22.718 314.175 23.878
202409 177.806 315.301 186.215
202412 182.818 315.605 191.280
202503 142.324 319.799 146.959
202506 127.886 322.561 130.920
202509 235.121 324.800 239.039
202512 147.122 324.054 149.918
202603 133.847 330.213 133.847

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN514.48 mean?
Regeneron Pharmaceuticals (MEX:REGN) has a Cyclically Adjusted FCF per Share of MXN514.48 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Regeneron Pharmaceuticals' current Cyclically Adjusted FCF per Share is MXN514.48. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Cyclically Adjusted FCF per Share of MXN514.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cyclically Adjusted FCF per Share is MXN514.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MEX:REGN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN15,044.82, compared to a current price of MXN10,835.99 — trading 28% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN514.48. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MEX:REGN), the current Cyclically Adjusted FCF per Share is MXN514.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (MEX:REGN) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of MXN10,835.99 is trading 28% below its estimated GF Value™ of MXN15,044.82. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:REGN:

  • Cyclically Adjusted FCF per Share: MXN514.48
  • GF Value™: MXN15,044.82 vs. price of MXN10,835.99 (28% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the MEX:REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for MEX:REGN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10,835.99
Price
MXN15,044.82
GF Value